Table 2.

Clinical parameters for patient samples.

Sample number	FAB	Sex	Age	Primary / Secondary?	WBC	Karyotype	Cytogenetic risk group	Treatment Intensity	Clinical Outcome
2	M4e	M	51	Primary	91.8	50,XY,+6,+8,+13, inv(16)(pl3q22),+ 22[10]	Favourable	intensive	CR
3	M4	M	33	Primary	71	46,XY,inv(16)(p1 3q22)[10]	Favourable	intensive	CR
5	M4e	M	42	Secondary	107.4	46,XY,inv(16)(pl3q22)[10]	Favourable	intensive	CR
7	unknown	M	81	Primary	40	46,XY [20]	Intermediate	non-intensive	Induction death
8	M4	F	69	Primary	73.5	45,XX,-7[13]	Adverse	non-intensive	Resistant disease
9	unknown	M	85	Primary	45.8	46,XY [20]	Intermediate	non-intensive	CR
10	unknown	F	80	Secondary	89.9			non-intensive	Induction death
11	M1	M	77	Primary	130	46,XY [20]	Intermediate	non-intensive	CR
15	M4	F	72	Relapse	104	46,XX [20]	Intermediate	non-intensive	Resistant disease
16	M1	M	48	Primary	171.5	46,XY [20] FLT3ITD positive	Intermediate	intensive	Resistant disease
17	M5a	M	62	Primary	69.5	46,XY,t(9;11)(p21;q23)[10] ---	Intermediate	intensive	.

WBC: white blood cell count, AMML: acute myelomonocytic leukemia, CR: complete remission, Res Dis: residual disease